LPL rs268: Understanding the Asn291Ser Genetic Variant
The rs268 variant, also known as Asn291Ser, is a genetic change in the LPL gene that affects the structure of the lipoprotein lipase enzyme. Research has associated this variant with variations in lipid levels, such as HDL cholesterol and triglycerides, and potential influences on cardiovascular health.
What each genotype means
Typical lipid enzyme activity
You carry two copies of the common reference allele for this variant in the LPL gene. In population studies, this genotype is associated with baseline lipoprotein lipase catalytic activity and standard baseline risk for altered HDL cholesterol and triglyceride levels relative to this specific locus. Because cardiovascular and metabolic health depend on thousands of interacting genetic markers and lifestyle factors, having this typical genotype does not eliminate risk for dyslipidemia or heart disease.
Carried by approximately 96% to 97% of individuals of European ancestry and exceeds 99% in East Asian and African populations.
Mildly reduced LPL activity
You carry one copy of the missense variant historically referred to as Asn291Ser (or Asn318Ser). Research indicates this alteration confers a partial reduction in lipoprotein lipase catalytic efficiency, which has been statistically linked in observational studies to modest decreases in HDL ("good") cholesterol, higher plasma triglyceride levels, and a slightly higher relative risk of ischemic heart disease, particularly among European cohorts. However, the real-world clinical significance remains modest and variable, meaning many carriers maintain normal blood lipid panels depending on overall diet, exercise, and broader genetic background.
Carried by approximately 3% to 4% of people of European ancestry (reaching up to ~4% in Finnish cohorts), while it is rarely observed in East Asian and African ancestries.
Significantly reduced LPL activity
You carry two copies of the missense variant in the LPL gene, which in laboratory functional assays substantially decreases lipoprotein lipase enzyme activity. In published cohorts, individuals with two copies show an increased statistical likelihood of exhibiting atherogenic dyslipidemia characterized by elevated circulating triglycerides and low HDL cholesterol. While this genotype contributes to a more atherogenic lipid profile in epidemiological research, clinical presentation varies widely, and standard clinical fasting lipid panels remain the appropriate tool for evaluating actual circulating cholesterol and triglyceride levels.
Very rare across all global ancestries, occurring in fewer than 1 in 2,500 people of European descent and exceptionally rarely elsewhere.
What is rs268 and Where is it Located?
The rs268 variant is a single-nucleotide polymorphism (SNP) located within the LPL gene on chromosome 8. Specifically, this variant occurs in exon 6 of the gene and results in a missense mutation where the amino acid asparagine is replaced by serine at position 291 of the protein sequence. Because of this change, it is frequently referred to in scientific literature as Asn291Ser. The LPL gene itself spans approximately 35 kilobases and contains 10 exons. This specific variant is considered a coding change, meaning it alters the primary sequence of the protein, which can potentially impact the protein's folding, stability, or catalytic function. Researchers study this site because it is located near the ligand-binding region of the enzyme, suggesting that even small changes here could have functional consequences for how the body processes fats.
The Role of the LPL Gene
The LPL gene provides instructions for making the lipoprotein lipase enzyme. This enzyme plays a critical role in lipid metabolism by breaking down triglycerides, which are fats carried in the blood by lipoproteins like chylomicrons and very-low-density lipoproteins (VLDL). By hydrolyzing these triglycerides, the enzyme releases free fatty acids that can be used by tissues for energy or stored in fat cells. Additionally, the activity of this enzyme is closely linked to the production of high-density lipoprotein (HDL) cholesterol, often referred to as 'good' cholesterol. When LPL function is impaired, it can lead to an accumulation of triglycerides in the bloodstream and a corresponding decrease in HDL levels. Because of its central role in clearing fats from the blood, variations in the LPL gene are frequently investigated as potential contributors to dyslipidemia and related metabolic conditions.
Research Associations and Evidence Strength
Scientific research has explored the association between rs268 and various health traits, including lipid profiles and cardiovascular outcomes. Meta-analyses have suggested that carriers of the 291Ser allele may exhibit modestly adverse lipid profiles, characterized by higher triglyceride levels and lower HDL cholesterol. Some studies have also investigated links between this variant and an increased risk of ischemic heart disease or type 2 diabetes, though the evidence is often described as limited or mixed. For instance, while some meta-analyses have reported statistically significant associations with coronary heart disease or Alzheimer's disease, others have found only marginal or null results. It is important to note that these associations are statistical observations across large populations and do not imply a direct cause-and-effect relationship for any single individual. The impact of this variant may also be influenced by environmental factors, such as age and weight gain, which can exacerbate the underlying lipid-related effects.
Population Frequency
The frequency of the rs268 variant varies across different ancestral groups. In many European populations, the minor allele frequency is relatively low, typically ranging between 0.015 and 0.02. Research has noted that the frequency can differ significantly even within European subgroups; for example, some studies have identified higher frequencies in Finnish populations compared to other European samples. Because this variant is relatively rare, large-scale studies are often required to achieve sufficient statistical power to detect its effects. The distribution of such variants highlights the importance of considering population structure when interpreting genetic data, as the prevalence of specific alleles can be influenced by historical patterns of migration, genetic drift, and natural selection.
Interpreting Your Genetic Information
Understanding your genetic variants can be an educational experience, but it is essential to maintain a balanced perspective. The presence of the rs268 variant does not constitute a medical diagnosis, nor does it guarantee that an individual will develop any specific health condition. Many factors, including diet, physical activity, smoking status, and other genetic markers, contribute to lipid levels and cardiovascular health. If you have concerns about your lipid profile or cardiovascular risk, the most appropriate step is to consult with a healthcare professional. They can interpret your clinical blood work and family history in the context of your overall health. Never use genetic information to make decisions about medication or treatment without first discussing them with your doctor or a qualified pharmacist, as they are best equipped to provide personalized medical guidance.
How common is this variant?
The minor allele frequency for rs268 is approximately 0.015 to 0.02 in European populations, though it shows variation across different ancestral groups.
Frequently asked questions
Is rs268 a cause of heart disease?
Research suggests a statistical association between the rs268 variant and altered lipid profiles, which are risk factors for heart disease. However, it is not a direct cause, and many other genetic and lifestyle factors play a much larger role in cardiovascular health.
Can I change my risk if I have the rs268 variant?
Genetic variants are fixed, but the health outcomes associated with them are often influenced by lifestyle. Maintaining a heart-healthy diet, regular exercise, and managing weight are standard recommendations for improving lipid profiles regardless of your genotype.
Should I get tested for the LPL rs268 variant?
Routine genetic testing for this specific variant is not standard clinical practice. If you are concerned about your cardiovascular risk, focus on clinical screenings like cholesterol panels, which provide actionable data for your doctor.
Does this variant affect how I should take medication?
There is no current clinical guidance suggesting that rs268 dictates specific medication dosing. Always consult your physician or pharmacist before making any changes to your prescribed medications.
Sources & further reading
Educational information only, last refreshed 10/20/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs268?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in LPL
A functional gain-of-function variant in the LPL gene that disrupts a microRNA-410 seed site, leading to increased LPL expression, lower plasma triglycerides, higher HDL cholesterol, and potential protective effects against hepatocellular carcinoma in specific clinical contexts.
Lipoprotein lipase S447X (often referred to as S474X in older literature) variant affects triglyceride clearance.
A common variant in the LPL gene that helps lower triglyceride levels and provides protection against heart disease.
This variant in the lipoprotein lipase gene is studied for its interaction with diet and lifestyle interventions in the context of obesity management.